Titlebook: Non-Hodgkin Lymphoma; Pathology, Imaging, Andrew M. Evens,Kristie A. Blum Book 2015 Springer International Publishing Switzerland 2015 Epi

交響樂(lè)

chastise

補(bǔ)充

Agnosia

Management of Diffuse Large B-Cell Lymphoma (DLBCL),incorporation of the CD20 antibody rituximab at the beginning of this century has considerably improved the outcome of all patients with DLBCL: Depending on the prognostic subgroup, only half to one-third of the patients die of their DLBCL compared to pre-rituximab era. Treatment is usually tailored

圓錐體

Current Management of Peripheral T-Cell Lymphomas,phomas (NHL) in Western countries. Although PTCLs are associated with poor prognosis, outcomes vary with disease subtype. The standard of care has been anthracycline-based induction combination chemotherapy, however, with the exception of low-risk ALK-positive anaplastic large cell lymphoma, relapse

偏狂癥

Post-transplant Lymphoproliferative Disorders,n and include a range of diseases from benign proliferations to malignant lymphomas. Risk factors for developing PTLD include Epstein-Barr virus (EBV) infection, recipient age, transplanted organ, type of immunosuppression, and genetics. Uncontrolled proliferation of EBV-infected B cells is implicat

毀壞

時(shí)間等

Expurgate

Brian C.-H. Chiu,Ningqi Houitalism. During the 1980s, Rosenhead (1982), Rosenhead and Thunhurst (1982), and Tinker and Lowe (1984) sustained this critical barrage against the traditional approach. Tinker and Lowe, for example, accused traditional management thinkers of being dominated by a technocratic consciousness and of ha

小蟲(chóng)

Sarah L. Ondrejka,Eric D. Hsially happened. The purpose of the chapter, in any case, is to demonstrate the logic of use of the methodologies rather than to seek to provide a thorough and “accurate” exposition of the events that took place. What the reader gets lies somewhere between description of actual interventions and what